Werewolf Therapeutics Inc (HOWL) Stock Analysis
Verdict: AVOID
Severe cash burn ($60.3M/year) against $58M cash reserves creates acute dilution risk, overshadowing pipeline progress and earnings surprises.
Investment score: 37/100
Analysis as of
Is Werewolf Therapeutics Inc stock worth reviewing? AI model thesis
Werewolf Therapeutics faces a tight liquidity runway with annual free cash flow burn of -$60.3M vs $58.0M cash, driving severe dilution risk despite positive clinical platform potential.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Werewolf Therapeutics Inc opportunities and risks
What speaks for HOWL
- PREDATOR INDUKINE Platform Validation
What speaks against HOWL
- Acute Cash Runway Depletion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HOWL | n/a | 2.1x | n/a | 86.4% | -164.8% | -67.5% |
| CLNN | n/a | 250.4x | n/a | -110.2% | -20059.9% | -32.4% |
| TIL | n/a | 0.0x | n/a | 0.0% | 0.0% | -48.5% |
| ELTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -111.7% |
| ANVS | n/a | 0.0x | n/a | 0.0% | 0.0% | -98.0% |
| MGX | n/a | 3.2x | n/a | 74.3% | -689.2% | -198.2% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -98.0% |
Frequently asked questions about Werewolf Therapeutics Inc (HOWL)
Is HOWL stock a good investment?
The cached TradeMates AI model rates Werewolf Therapeutics Inc as AVOID with an investment score of 37/100. Werewolf Therapeutics faces a tight liquidity runway with annual free cash flow burn of -$60.3M vs $58.0M cash, driving severe dilution risk despite positive clinical platform potential. This is algorithmic model output, not personal investment advice.
Is HOWL stock a buy?
The TradeMates model verdict for HOWL is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.